The pharmacological agent outperforms current drugs in most of cases, show multiple experiments
A new pharmacological agent demonstrates promising results for the prevention of a wide range of heart rhythm disorders, including both cardiac and brain injury-induced arrhythmias. Furthermore, the compound (SS-68) demonstrates significant activity in conditions of reduced blood flow to the heart caused by obstructed arteries.
The study, conducted by a research team led by Dr Saida Bogus of the Kuban State Medical University in Russia, is published in the open-access journal Research Results in Pharmacology.
Each year, more than 17 million people from around the globe (mostly Europe and the USA) die of cardiovascular diseases and related complications, according to the World Health Organization. In Russia, about 3 out of 1,000 people suffer from the most common and malignant heart rhythm disorder: atrial fibrillation (AF), where the count is expected to at least double in the next 30 years. While sometimes lacking symptoms, atrial fibrillation could generally be recognised by a racing, irregular heartbeat, dizziness, fatigue, shortness of breath and chest pain, thereby largely compromising the quality of one’s life. The disorder could also lead to various complications, including dementia, stroke and heart failure.
Currently, the drugs administered to AF patients have major deficiencies, including narrow therapeutic windows, which means that even minimal imprecision in the dosage could result in unacceptable toxicity. Hence, patients need to be closely monitored and have their doses adjusted on a regular basis.
In their study, the team turned to the aminoindole derivatives to look for an alternative compound. This chemical group has already shown a significant potential in terms of cardio-pharmacological activity.
Having tested the SS-68 compound on multiple occasions in different animals, the researchers report that it has a pronounced antiarrhythmic effect and is able to bring the electrical activity of the heart back to normal and, in most cases, outperforming the reference drugs used in clinical practice: amiodarone, lidocaine, aymaline, ethacizine, etmozine and quinidine anaprilin.
Further, in brain injury-induced arrhythmias, the compound was found to reduce the episodes of epilepsy. It was also observed to have a positive effect in clogged blood vessels where it is reported to have successfully increased the coronary blood flow. In addition, the compound managed to decrease the area of necrosis in the heart tissue caused by a heart attack.
“To date, there have been significant achievements of Russian and foreign pharmacologists, chemists and clinicians in creating and introducing into the practical medicine a number of antiarrhythmic drugs different by their chemical structure, nature, spectrum, activity and mechanism of action; nevertheless, one of the most important tasks of modern pharmacology is searching for and developing new highly active substances of the corresponding action,” explain the scientists.
“Special attention should be paid to an in-depth study of the molecular mechanisms of action of this compound,” they conclude.
A paper looking further into the molecular mechanisms of the antiarrhythmic action of SS-68 prepared by the same research team is currently in press with Research Results in Pharmacology.
Learn more: New promising compound against heart rhythm disorders and clogged arteries
The Latest on: Pharmacological agent
[google_news title=”” keyword=”pharmacological agent” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Pharmacological agent
- Biodexa Enters Into Exclusive License to eRapa™, a Phase 3 Ready Asset for the Treatment of Familial Adenomatous Polyposis (FAP)on April 26, 2024 at 5:30 am
Biodexa Enters Into Exclusive License to eRapa™, a Phase 3 Ready Asset for theTreatment of Familial Adenomatous Polyposis (FAP) Worldwide rights come with $17 million in non-dilutive grant funding for ...
- Capital One Initiates Coverage of Heron Therapeutics (HRTX) with Overweight Recommendationon April 23, 2024 at 10:51 am
Fintel reports that on April 23, 2024, Capital One initiated coverage of Heron Therapeutics (NasdaqCM:HRTX) with a Overweight recommendation. Analyst Price Forecast Suggests 175.68% Upside As of April ...
- Breakthrough rice bran nanoparticles show promise as affordable and targeted anticancer agenton April 23, 2024 at 10:45 am
Plant-derived nanoparticles have demonstrated significant anticancer effects. Researchers recently developed rice bran-derived nanoparticles (rbNPs) that efficiently suppressed cell proliferation and ...
- ACP: Recommendations Developed for Newer Type 2 Diabetes Medicationson April 22, 2024 at 11:30 pm
In a clinical guideline issued by the American College of Physicians (ACP) and published online April 19 in the Annals of Internal Medicine, recommendations are presented regarding newer pharmacologic ...
- AAN 2024: Troriluzole may be taken with food, data suggeston April 22, 2024 at 7:47 am
Troriluzole can be taken with food and appears to have better properties than approved versions of once-a-day riluzole, data showed.
- Astellas’ generic Myrbetriq defence knocked back againon April 21, 2024 at 10:34 pm
Myrbetriq – sold as Betanis and Betmiga in some markets – is an extended-release selective beta3-adrenoceptor agonist therapy used to treat overactive bladder with symptoms of urinary incontinence, ...
- Review Highlights Benefits of Laser, Light Therapy for PCOS-Related Hirsutismon April 18, 2024 at 3:55 am
Laser and light hair treatments, with and without other treatments, improve hirsutism and related psychological measures in women with PCOS.
- Researchers find evidence a natural juice can help gut healthon April 17, 2024 at 8:08 am
A team of researchers at the University of Missouri is uncovering how the juice from red cabbage, long used in traditional medicine, can alleviate inflammation-associated digestive health conditions ...
- Nanoparticle delivery of FZD4 to lung endothelial cells inhibits lung cancer progression and metastaseson April 16, 2024 at 2:28 pm
A recent study from the lab of Tanya Kalin, MD, Ph.D., professor of Child Health and Internal Medicine at the University of Arizona College of Medicine—Phoenix, has shown potential to improve ...
via Bing News